Comparative Dosimetric Analysis and Normal Tissue Complication Probability Modelling of Four-Dimensional Computed Tomography Planning Scans Within the UK NeoSCOPE Trial-Reference-Cited by-同舟云学术

Comparative Dosimetric Analysis and Normal Tissue Complication Probability Modelling of Four-Dimensional Computed Tomography Planning Scans Within the UK NeoSCOPE Trial

Published:2020-12 Issue:12 Volume:32 Page:828-834
ISSN:0936-6555
Container-title:Clinical Oncology
language:en
Short-container-title:Clinical Oncology

Author:

Nicholas O.,Bowden C.,Selby A.,Bodger O.,Lewis P.,Webster R.,Radhakrishna G.,Jones G.,Hawkins M.,Mukherjee S.,Crosby T.,Gwynne S.

Funder

South West Wales Cancer Fund

MRC

Publisher

Elsevier BV

Subject

Radiology Nuclear Medicine and imaging,Oncology

Reference31 articles.

1. Benchmarking complications associated with esophagectomy;Low;Ann Surg,2019

2. Neoadjuvant chemoradiotherapy in resectable oesophageal cancer patients: UK practice;Bowden;Eur J Surg Oncol,2016

3. Investigating the potential impact of four-dimensional computed tomography (4DCT) on toxicity, outcomes and dose escalation for radical lung cancer radiotherapy;Cole;Clin Oncol,2014

4. Four-dimensional measurement of the displacement of internal fiducial markers during 320-multislice computed tomography scanning of thoracic esophageal cancer;Yamashita;Int J Radiat Oncol Biol Phys,2011

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. SCOPE 2 – Still Answering the Unanswered Questions in Oesophageal Radiotherapy? SCOPE 2: a Randomised Phase II/III Trial to Study Radiotherapy Dose Escalation in Patients with Oesophageal Cancer Treated with Definitive Chemoradiation with an Embedded Phase II Trial for Patients with a Poor Early Response using Positron Emission Tomography/Computed Tomography;Clinical Oncology;2022-07

2. An in-silico assessment of the dosimetric benefits of MR-guided radiotherapy for esophageal cancer patients;Radiotherapy and Oncology;2021-09

3. Image-Guided Radiotherapy – The Unsung Hero of Radiotherapy Development;Clinical Oncology;2020-12